Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 5/20 | 0.65 |
| ▸ | PYGM | P11217 | 3/20 | 0.64 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.52 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.52 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4179026 | 1.00 | TK2 (0.65) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL4179022 | 1.00 | TK2 (0.65) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL4181060 | 0.92 | TK2 (0.67) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL4181065 | 0.92 | TK2 (0.67) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL4181063 | 0.92 | TK2 (0.67) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL4171991 | 0.87 | PYGM (0.65) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL4179822 | 0.87 | PYGM (0.65) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL4179817 | 0.87 | PYGM (0.65) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL4171997 | 0.87 | PYGM (0.65) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL4179818 | 0.87 | PYGM (0.65) | TK2PYGMSLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090004137-A1 | Uridine Derivatives as Antiviral Drugs Against a Flaviviridae, Especially Hcv | INSTITUTE NATIONAL DE LA SAINTE ET DE LA RECHDERCHE MEDICALE (FR) | 2009-01-01 | — | — | US | claimed |
| EP-1674104-A1 | Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2006-06-28 | — | — | EP | claimed |
| US-20090004137-A1 | Uridine Derivatives as Antiviral Drugs Against a Flaviviridae, Especially Hcv | INSTITUTE NATIONAL DE LA SAINTE ET DE LA RECHDERCHE MEDICALE (FR) | 2009-01-01 | — | — | US | disclosed |
| EP-1674104-A1 | Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2006-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004137-A1 | Uridine Derivatives as Antiviral Drugs Against a Flaviviridae, Especially Hcv | NUDT1, UMPS, UPP1 | TK2 252/4885PYGM 1203/4885SLC28A1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.